Oral Surgery, General Dentistry Program, Batterjee Medical College, Jeddah, Makkah, 21442, Saudi Arabia.
Oral and Maxillofacial Surgery, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, 442001, India.
F1000Res. 2024 Oct 30;13:106. doi: 10.12688/f1000research.145643.3. eCollection 2024.
Surgical removal of an impacted third molar is one of the most common oral surgical procedures performed in dental offices. The postoperative phase is often associated with severe inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) are usually prescribed to manage postoperative discomfort. NSAIDs have been associated with gastrointestinal bleeding, renal function disturbances, and platelet count reductions. Thus, the present study demonstrates the utility of aescin in managing postoperative discomfort after the surgical removal of impacted mandibular third molars.This study aimed to correlate and compare the impact of aescin and diclofenac on salivary PGE2 levels and serum C-reactive protein levels after surgical extraction of the mandibular third molar. The study will also evaluate and compare the effectiveness of individual drug therapy in managing postoperative pain, swelling and mouth opening.
The planned study is a single-center, double-blind, randomized, parallel, prospective clinical trial. Each patient will be prescribed either diclofenac sodium 150 mg/day or aescin (escin) 120 mg/day to be taken orally in divided doses for five days after surgically removing the impacted mandibular third molar.Pain will be assessed using a visual analog scale. Facial swelling and mouth opening will be recorded using a metric scale with standardized reference points. ELISA (enzyme-linked immunosorbent assay (ELISA) will be employed to measure salivary Prostaglandin E2 and serum C-reactive protein levels. All parameters will be recorded preoperatively (T0) on the second postoperative day (T1) and fifth postoperative day (T2).
The proposed study is expected to show a clinically acceptable response to the administration of aescin for the management of postoperative discomfort compared to diclofenac sodium after third molar surgery.The proposed study is expected to positively manipulate the levels of salivary Prostaglandin E2 and serum C-reactive protein, which are reliable inflammatory markers.The outcome of this study may provide an efficacious and safe alternative to conventional nonsteroidal anti-inflammatory drugs for managing postoperative discomfort following third molar surgery.
拔除阻生第三磨牙是牙科诊室最常见的口腔外科手术之一。术后阶段常伴有严重炎症。通常会开非甾体抗炎药（NSAIDs）来缓解术后不适。NSAIDs 与胃肠道出血、肾功能紊乱和血小板计数减少有关。因此，本研究旨在展示七叶皂苷在管理下颌阻生第三磨牙拔除术后不适方面的效用。
本研究旨在比较和比较七叶皂苷和双氯芬酸对下颌第三磨牙拔除术后唾液 PGE2 水平和血清 C 反应蛋白水平的影响。本研究还将评估和比较两种药物单独治疗在管理术后疼痛、肿胀和张口度方面的效果。
本计划研究是一项单中心、双盲、随机、平行、前瞻性临床试验。每位患者将被开处方服用双氯芬酸钠 150mg/天或七叶皂苷（七叶皂苷）120mg/天，在手术拔除下颌阻生第三磨牙后分剂量口服 5 天。使用视觉模拟评分法评估疼痛。使用带有标准化参考点的度量量表记录面部肿胀和张口度。使用酶联免疫吸附试验（ELISA）测量唾液前列腺素 E2 和血清 C 反应蛋白水平。所有参数将在术前（T0）、术后第 2 天（T1）和第 5 天（T2）记录。
与手术后使用双氯芬酸钠相比，预计七叶皂苷在管理第三磨牙手术后的术后不适方面会产生临床可接受的反应。
预计该研究将积极影响唾液前列腺素 E2 和血清 C 反应蛋白的水平，这些是可靠的炎症标志物。
这项研究的结果可能为管理第三磨牙手术后的术后不适提供一种有效且安全的替代传统非甾体抗炎药的方法。
